pubmed-article:6389719 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:6389719 | lifeskim:mentions | umls-concept:C0008947 | lld:lifeskim |
pubmed-article:6389719 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
pubmed-article:6389719 | lifeskim:mentions | umls-concept:C0032150 | lld:lifeskim |
pubmed-article:6389719 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:6389719 | pubmed:dateCreated | 1985-1-2 | lld:pubmed |
pubmed-article:6389719 | pubmed:abstractText | The clindamycin dose-response curves observed with both chloroquine-resistant and chloroquine-susceptible strains of Plasmodium falciparum in vitro demonstrated a plateau region that extended from 10(-2) to 10(1) micrograms/ml of drug (22 nM to 22 microM). Similar dose-response curves were also observed with the three major metabolites of clindamycin (clindamycin sulfoxide, de-N-methyl clindamycin, and de-N-methyl clindamycin sulfoxide). The position of this plateau was time dependent and rose from 20%-25% to 90%-95% inhibition of parasite growth between 24 and 72 hr of exposure to the drug. Clinidamycin treatment reduced plasmodial protein and nucleic acid synthesis (as measured by the incorporation of [3H]isoleucine and [3H]hypoxanthine, respectively) but did not interfere with knob formation. The combination of quinine plus a fixed concentration of clindamycin (0.1 microgram/ml) inhibited growth of the quinine-resistant Indochina I strain, although most of the antiplasmodial activity observed at quinine concentrations less than 50 ng/ml (154 nM) could be attributed to clindamycin alone. | lld:pubmed |
pubmed-article:6389719 | pubmed:language | eng | lld:pubmed |
pubmed-article:6389719 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6389719 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:6389719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6389719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6389719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6389719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6389719 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:6389719 | pubmed:month | Dec | lld:pubmed |
pubmed-article:6389719 | pubmed:issn | 0022-1899 | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:KrogstadD JDJ | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:GluzmanI YIY | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:BrodaskyT FTF | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:ParquetteA... | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:SeabergL SLS | lld:pubmed |
pubmed-article:6389719 | pubmed:author | pubmed-author:PhillipsG... | lld:pubmed |
pubmed-article:6389719 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:6389719 | pubmed:volume | 150 | lld:pubmed |
pubmed-article:6389719 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:6389719 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:6389719 | pubmed:pagination | 904-11 | lld:pubmed |
pubmed-article:6389719 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:meshHeading | pubmed-meshheading:6389719-... | lld:pubmed |
pubmed-article:6389719 | pubmed:year | 1984 | lld:pubmed |
pubmed-article:6389719 | pubmed:articleTitle | Clindamycin activity against chloroquine-resistant Plasmodium falciparum. | lld:pubmed |
pubmed-article:6389719 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:6389719 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6389719 | lld:pubmed |